Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 312

1.

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia.

Branford S, Kim DDH, Apperley JF, Eide CA, Mustjoki S, Ong ST, Nteliopoulos G, Ernst T, Chuah C, Gambacorti-Passerini C, Mauro MJ, Druker BJ, Kim DW, Mahon FX, Cortes J, Radich JP, Hochhaus A, Hughes TP; International CML Foundation Genomics Alliance.

Leukemia. 2019 Jun 17. doi: 10.1038/s41375-019-0512-y. [Epub ahead of print] Review.

PMID:
31209280
2.

Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib.

Kok CH, Yeung DT, Lu L, Watkins DB, Leclercq TM, Dang P, Saunders VA, Reynolds J, White DL, Hughes TP.

Blood Adv. 2019 May 28;3(10):1610-1621. doi: 10.1182/bloodadvances.2019000195.

3.

Modelling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission.

Shanmuganathan N, Braley JA, Yong AS, Hiwase DK, Yeung DT, Ross DM, Hughes TP, Branford S.

Blood. 2019 Apr 9. pii: blood.2019000120. doi: 10.1182/blood.2019000120. [Epub ahead of print] No abstract available.

PMID:
30967368
4.

Global warming impairs stock-recruitment dynamics of corals.

Hughes TP, Kerry JT, Baird AH, Connolly SR, Chase TJ, Dietzel A, Hill T, Hoey AS, Hoogenboom MO, Jacobson M, Kerswell A, Madin JS, Mieog A, Paley AS, Pratchett MS, Torda G, Woods RM.

Nature. 2019 Apr;568(7752):387-390. doi: 10.1038/s41586-019-1081-y. Epub 2019 Apr 3.

PMID:
30944475
5.

Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia.

Ross DM, Pagani IS, Irani YD, Clarson J, Leclercq T, Dang P, McLean J, Saunders VA, Carne L, Reynolds J, Ritchie DS, White DL, Branford S, Hughes TP, Yong ASM.

Br J Haematol. 2019 Mar 27. doi: 10.1111/bjh.15894. [Epub ahead of print] No abstract available.

PMID:
30916385
6.

Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI.

Shanmuganathan N, Branford S, Hughes TP, Hiwase D.

Blood Adv. 2019 Feb 12;3(3):370-374. doi: 10.1182/bloodadvances.2018027516. No abstract available.

7.

Molecular monitoring in CML: how deep? How often? How should it influence therapy?

Shanmuganathan N, Hughes TP.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):168-176. doi: 10.1182/asheducation-2018.1.168. Review.

PMID:
30504306
8.

Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis.

Tvorogov D, Thomas D, Liau NPD, Dottore M, Barry EF, Lathi M, Kan WL, Hercus TR, Stomski F, Hughes TP, Tergaonkar V, Parker MW, Ross DM, Majeti R, Babon JJ, Lopez AF.

Sci Adv. 2018 Nov 28;4(11):eaat3834. doi: 10.1126/sciadv.aat3834. eCollection 2018 Nov.

9.

Molecular monitoring in CML: how deep? How often? How should it influence therapy?

Shanmuganathan N, Hughes TP.

Blood. 2018 Nov 15;132(20):2125-2133. doi: 10.1182/blood-2018-05-848630. Review.

PMID:
30429156
10.

Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant BCR-ABL1+ cell lines.

Lu L, Kok CH, Saunders VA, Wang J, McLean JA, Hughes TP, White DL.

Oncotarget. 2018 Oct 5;9(78):34735-34747. doi: 10.18632/oncotarget.26187. eCollection 2018 Oct 5.

11.

Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells.

Ross DM, Pagani IS, Shanmuganathan N, Kok CH, Seymour JF, Mills AK, Filshie RJ, Arthur CK, Dang P, Saunders VA, Braley J, Yong AS, Yeung DT, White DL, Grigg AP, Schwarer AP, Branford S, Hughes TP; Australasian Leukaemia and Lymphoma Group (ALLG).

Leukemia. 2018 Dec;32(12):2572-2579. doi: 10.1038/s41375-018-0264-0. Epub 2018 Oct 12.

PMID:
30315232
12.

Treatment-Free Remission After Second-Line Nilotinib Treatment.

Mahon FX, Hughes TP.

Ann Intern Med. 2018 Oct 2;169(7):510. doi: 10.7326/L18-0431. No abstract available.

PMID:
30285197
13.

Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia.

Hughes TP, Laneuville P, Rousselot P, Snyder DS, Rea D, Shah NP, Paar D, Abruzzese E, Hochhaus A, Lipton JH, Cortes JE.

Haematologica. 2019 Jan;104(1):93-101. doi: 10.3324/haematol.2018.188987. Epub 2018 Aug 9.

14.

BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia.

Pagani IS, Dang P, Kommers IO, Goyne JM, Nicola M, Saunders VA, Braley J, White DL, Yeung DT, Branford S, Hughes TP, Ross DM.

Haematologica. 2018 Dec;103(12):2026-2032. doi: 10.3324/haematol.2018.189787. Epub 2018 Jul 5.

15.

Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease.

Branford S, Wang P, Yeung DT, Thomson D, Purins A, Wadham C, Shahrin NH, Marum JE, Nataren N, Parker WT, Geoghegan J, Feng J, Shanmuganathan N, Mueller MC, Dietz C, Stangl D, Donaldson Z, Altamura H, Georgievski J, Braley J, Brown A, Hahn C, Walker I, Kim SH, Choi SY, Park SH, Kim DW, White DL, Yong ASM, Ross DM, Scott HS, Schreiber AW, Hughes TP.

Blood. 2018 Aug 30;132(9):948-961. doi: 10.1182/blood-2018-02-832253. Epub 2018 Jul 2.

PMID:
29967129
16.

Management of Pregnancy in Women With Chronic Myeloid Leukemia.

Ross DM, Burbury KL, Grigg AP, Hughes TP, Seymour JF.

J Clin Oncol. 2018 Sep 1;36(25):2657-2658. doi: 10.1200/JCO.2018.78.6137. Epub 2018 May 31. No abstract available.

PMID:
29851544
17.

Guidelines for whole genome bisulphite sequencing of intact and FFPET DNA on the Illumina HiSeq X Ten.

Nair SS, Luu PL, Qu W, Maddugoda M, Huschtscha L, Reddel R, Chenevix-Trench G, Toso M, Kench JG, Horvath LG, Hayes VM, Stricker PD, Hughes TP, White DL, Rasko JEJ, Wong JJ, Clark SJ.

Epigenetics Chromatin. 2018 May 28;11(1):24. doi: 10.1186/s13072-018-0194-0.

18.

Global warming transforms coral reef assemblages.

Hughes TP, Kerry JT, Baird AH, Connolly SR, Dietzel A, Eakin CM, Heron SF, Hoey AS, Hoogenboom MO, Liu G, McWilliam MJ, Pears RJ, Pratchett MS, Skirving WJ, Stella JS, Torda G.

Nature. 2018 Apr;556(7702):492-496. doi: 10.1038/s41586-018-0041-2. Epub 2018 Apr 18.

PMID:
29670282
19.

Increasing thermal stress for tropical coral reefs: 1871-2017.

Lough JM, Anderson KD, Hughes TP.

Sci Rep. 2018 Apr 17;8(1):6079. doi: 10.1038/s41598-018-24530-9.

20.

Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapy.

Eadie LN, Hughes TP, White DL.

Leukemia. 2018 Oct;32(10):2288-2291. doi: 10.1038/s41375-018-0101-5. Epub 2018 Mar 23. No abstract available.

PMID:
29654270
21.

The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro.

Eadie LN, Saunders VA, Branford S, White DL, Hughes TP.

Oncotarget. 2018 Feb 3;9(17):13423-13437. doi: 10.18632/oncotarget.24393. eCollection 2018 Mar 2.

22.

Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.

Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM.

Blood. 2018 Jul 26;132(4):393-404. doi: 10.1182/blood-2016-09-739086. Epub 2018 Mar 22.

23.

Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression.

McClure BJ, Heatley SL, Kok CH, Sadras T, An J, Hughes TP, Lock RB, Yeung D, Sutton R, White DL.

Br J Cancer. 2018 Apr;118(7):1000-1004. doi: 10.1038/s41416-018-0022-0. Epub 2018 Mar 13.

24.

Biogeographical disparity in the functional diversity and redundancy of corals.

McWilliam M, Hoogenboom MO, Baird AH, Kuo CY, Madin JS, Hughes TP.

Proc Natl Acad Sci U S A. 2018 Mar 20;115(12):3084-3089. doi: 10.1073/pnas.1716643115. Epub 2018 Mar 5.

25.

Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.

Mahon FX, Boquimpani C, Kim DW, Benyamini N, Clementino NCD, Shuvaev V, Ailawadhi S, Lipton JH, Turkina AG, De Paz R, Moiraghi B, Nicolini FE, Dengler J, Sacha T, Takahashi N, Fellague-Chebra R, Acharya S, Wong S, Jin Y, Hughes TP.

Ann Intern Med. 2018 Apr 3;168(7):461-470. doi: 10.7326/M17-1094. Epub 2018 Feb 20.

PMID:
29459949
26.

ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells.

Eadie LN, Dang P, Goyne JM, Hughes TP, White DL.

PLoS One. 2018 Jan 31;13(1):e0192180. doi: 10.1371/journal.pone.0192180. eCollection 2018. Erratum in: PLoS One. 2018 Aug 31;13(8):e0203583.

27.

A dual role for the N-terminal domain of the IL-3 receptor in cell signalling.

Broughton SE, Hercus TR, Nero TL, Kan WL, Barry EF, Dottore M, Cheung Tung Shing KS, Morton CJ, Dhagat U, Hardy MP, Wilson NJ, Downton MT, Schieber C, Hughes TP, Lopez AF, Parker MW.

Nat Commun. 2018 Jan 26;9(1):386. doi: 10.1038/s41467-017-02633-7.

28.

Spatial and temporal patterns of mass bleaching of corals in the Anthropocene.

Hughes TP, Anderson KD, Connolly SR, Heron SF, Kerry JT, Lough JM, Baird AH, Baum JK, Berumen ML, Bridge TC, Claar DC, Eakin CM, Gilmour JP, Graham NAJ, Harrison H, Hobbs JA, Hoey AS, Hoogenboom M, Lowe RJ, McCulloch MT, Pandolfi JM, Pratchett M, Schoepf V, Torda G, Wilson SK.

Science. 2018 Jan 5;359(6371):80-83. doi: 10.1126/science.aan8048.

PMID:
29302011
29.

ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure.

Marum JE, Yeung DT, Purins L, Reynolds J, Parker WT, Stangl D, Wang PPS, Price DJ, Tuke J, Schreiber AW, Scott HS, Hughes TP, Branford S.

Blood Adv. 2017 Jul 31;1(18):1369-1381. doi: 10.1182/bloodadvances.2017006825. eCollection 2017 Aug 8.

30.

Large-scale bleaching of corals on the Great Barrier Reef.

Hughes TP, Kerry JT, Simpson T.

Ecology. 2018 Feb;99(2):501. doi: 10.1002/ecy.2092. Epub 2017 Dec 18.

PMID:
29155453
31.

First Approved Kinase Inhibitor for AML.

Rasko JEJ, Hughes TP.

Cell. 2017 Nov 16;171(5):981. doi: 10.1016/j.cell.2017.11.007.

32.

A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH.

Sadras T, Heatley SL, Kok CH, McClure BJ, Yeung D, Hughes TP, Sutton R, Ziegler DS, White DL.

Cancer Genet. 2017 Oct;216-217:86-90. doi: 10.1016/j.cancergen.2017.07.008. Epub 2017 Jul 31.

PMID:
29025600
33.

High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment.

Heatley SL, Sadras T, Kok CH, Nievergall E, Quek K, Dang P, McClure B, Venn N, Moore S, Suttle J, Law T, Ng A, Muskovic W, Norris MD, Revesz T, Osborn M, Moore AS, Suppiah R, Fraser C, Alvaro F, Hughes TP, Mullighan CG, Marshall GM, Pozza LD, Yeung DT, Sutton R, White DL.

Haematologica. 2017 Dec;102(12):e490-e493. doi: 10.3324/haematol.2016.162925. Epub 2017 Sep 21. No abstract available.

34.

Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions.

Sadras T, Heatley SL, Kok CH, Dang P, Galbraith KM, McClure BJ, Muskovic W, Venn NC, Moore S, Osborn M, Revesz T, Moore AS, Hughes TP, Yeung D, Sutton R, White DL.

Cancer Lett. 2017 Nov 1;408:92-101. doi: 10.1016/j.canlet.2017.08.034. Epub 2017 Sep 1.

PMID:
28866095
35.

Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results.

Hughes TP, Leber B, Cervantes F, Spector N, Pasquini R, Clementino NCD, Schwarer AP, Dorlhiac-Llacer PE, Mahon FX, Rea D, Guerci-Bresler A, Kamel-Reid S, Bendit I, Acharya S, Glynos T, Dalal D, Branford S, Lipton JH.

Leukemia. 2017 Nov;31(11):2529-2531. doi: 10.1038/leu.2017.247. Epub 2017 Aug 3. No abstract available.

36.

A Method for Next-Generation Sequencing of Paired Diagnostic and Remission Samples to Detect Mitochondrial DNA Mutations Associated with Leukemia.

Pagani IS, Kok CH, Saunders VA, Van der Hoek MB, Heatley SL, Schwarer AP, Hahn CN, Hughes TP, White DL, Ross DM.

J Mol Diagn. 2017 Sep;19(5):711-721. doi: 10.1016/j.jmoldx.2017.05.009. Epub 2017 Jul 18.

PMID:
28732215
37.

Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd.

Hughes TP, Munhoz E, Aurelio Salvino M, Ong TC, Elhaddad A, Shortt J, Quach H, Pavlovsky C, Louw VJ, Shih LY, Turkina AG, Meillon L, Jin Y, Acharya S, Dalal D, Lipton JH.

Br J Haematol. 2017 Oct;179(2):219-228. doi: 10.1111/bjh.14829. Epub 2017 Jul 12.

38.

Coral reefs in the Anthropocene.

Hughes TP, Barnes ML, Bellwood DR, Cinner JE, Cumming GS, Jackson JBC, Kleypas J, van de Leemput IA, Lough JM, Morrison TH, Palumbi SR, van Nes EH, Scheffer M.

Nature. 2017 May 31;546(7656):82-90. doi: 10.1038/nature22901. Review.

PMID:
28569801
39.

The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.

Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, Marzinzik AL, Pelle X, Donovan J, Zhu W, Buonamici S, Hassan AQ, Lombardo F, Iyer V, Palmer M, Berellini G, Dodd S, Thohan S, Bitter H, Branford S, Ross DM, Hughes TP, Petruzzelli L, Vanasse KG, Warmuth M, Hofmann F, Keen NJ, Sellers WR.

Nature. 2017 Mar 30;543(7647):733-737. doi: 10.1038/nature21702. Epub 2017 Mar 22.

PMID:
28329763
40.

Global warming and recurrent mass bleaching of corals.

Hughes TP, Kerry JT, Álvarez-Noriega M, Álvarez-Romero JG, Anderson KD, Baird AH, Babcock RC, Beger M, Bellwood DR, Berkelmans R, Bridge TC, Butler IR, Byrne M, Cantin NE, Comeau S, Connolly SR, Cumming GS, Dalton SJ, Diaz-Pulido G, Eakin CM, Figueira WF, Gilmour JP, Harrison HB, Heron SF, Hoey AS, Hobbs JA, Hoogenboom MO, Kennedy EV, Kuo CY, Lough JM, Lowe RJ, Liu G, McCulloch MT, Malcolm HA, McWilliam MJ, Pandolfi JM, Pears RJ, Pratchett MS, Schoepf V, Simpson T, Skirving WJ, Sommer B, Torda G, Wachenfeld DR, Willis BL, Wilson SK.

Nature. 2017 Mar 15;543(7645):373-377. doi: 10.1038/nature21707.

41.

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.

Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ; IRIS Investigators.

N Engl J Med. 2017 Mar 9;376(10):917-927. doi: 10.1056/NEJMoa1609324.

42.

A unified model explains commonness and rarity on coral reefs.

Connolly SR, Hughes TP, Bellwood DR.

Ecol Lett. 2017 Apr;20(4):477-486. doi: 10.1111/ele.12751. Epub 2017 Mar 2.

PMID:
28251798
43.

Targeted therapies: Remembrance of things past - discontinuation of second-generation TKI therapy for CML.

Hughes TP, Ross DM.

Nat Rev Clin Oncol. 2017 Apr;14(4):201-202. doi: 10.1038/nrclinonc.2017.11. Epub 2017 Feb 7. No abstract available.

PMID:
28169304
44.

Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells.

Wang J, Lu L, Kok CH, Saunders VA, Goyne JM, Dang P, Leclercq TM, Hughes TP, White DL.

Haematologica. 2017 May;102(5):843-853. doi: 10.3324/haematol.2016.153270. Epub 2017 Feb 2.

45.

Comment on "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study".

Hughes A, Clarson J, Gargett T, Yu W, Brown MP, Lopez AF, Hughes TP, Yong AS.

Leuk Res. 2017 Apr;55:55-57. doi: 10.1016/j.leukres.2017.01.009. Epub 2017 Jan 9. No abstract available.

PMID:
28129558
46.

CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.

Hughes A, Clarson J, Tang C, Vidovic L, White DL, Hughes TP, Yong AS.

Blood. 2017 Mar 2;129(9):1166-1176. doi: 10.1182/blood-2016-10-745992. Epub 2017 Jan 3.

47.

CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients.

Barratt DT, Cox HK, Menelaou A, Yeung DT, White DL, Hughes TP, Somogyi AA.

Clin Pharmacokinet. 2017 Aug;56(8):977-985. doi: 10.1007/s40262-016-0494-0.

PMID:
27995529
48.

Response to 'Overexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics?'

Eadie LN, Hughes TP, White DL.

Leukemia. 2017 Mar;31(3):769-770. doi: 10.1038/leu.2016.335. Epub 2016 Dec 2. No abstract available.

PMID:
27909344
49.

ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines.

Eadie LN, Hughes TP, White DL.

PLoS One. 2016 Aug 18;11(8):e0161470. doi: 10.1371/journal.pone.0161470. eCollection 2016.

50.

The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment.

Eadie LN, Dang P, Saunders VA, Yeung DT, Osborn MP, Grigg AP, Hughes TP, White DL.

Leukemia. 2017 Jan;31(1):75-82. doi: 10.1038/leu.2016.179. Epub 2016 Jun 24.

PMID:
27416909

Supplemental Content

Loading ...
Support Center